Fate Therapeutics, Inc.
corporate_fare Company Profile
Fate Therapeutics, Inc. (NASDAQ:FATE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for FATE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for FATE spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Fate Posts $139M Cash, Mid-2028 Runway; FT819 Lupus Data Shows 100% Renal Response
- FT819 Hits 100% Month-6 Renal Response in Lupus Nephritis Cohort
- Fate Therapeutics Wins $15M CIRM Grant to Advance Lupus CAR-T Trial
- Fate Therapeutics Reports Q2 2026 Results: First Patient Dosed in Pivotal Lupus Nephritis Trial, Cash Runway into 2028
- Fate Doses First Lupus Nephritis Patient in Pivotal CAR T Trial
Financial Snapshot
Short Interest & Short Volume
8.32 days to coverFINRA reported short interest of 9,972,851 shares in FATE as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 38.1% of FATE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for FATE, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.
Prospectus Supplement for $100M ATM · Illustrative Dilution at $2.17
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →